UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy

Abstract

Our findings provided the first evidence that UCA1 may serve as an indicator of response to chemotherapy and prognosis of ovarian cancer. UCA1 may play an important role in the progression of ovarian cancer.

Role of long noncoding RNA UCA1 as a common molecular marker for lymph node metastasis and prognosis in various cancers: a meta-analysis

“…In the 13 potential candidate studies, 1 study was excluded because of inadequate data of HR with 95 % CI. Finally, according to the criteria for selection, a total of 12 studies were eligible [5–16]. …”

“…Moreover, UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis [15]. UCA1, significantly associated with LNM and OS, may function as on oncogene and a potential indicator of prognosis in some cancers, including colorectal cancer, esophageal squamous cell carcinoma, prostate cancer, hepatocellular carcinoma and ovarian cancer [5–16]. …”

Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma

“…Previous studies have indicated that lncRNAs play critical roles in malignant tumors including colorectal and ovarian cancer [5, 6]. However, the functions of lncRNAs in ccRCC development and metastasis have not been elucidated [7].…”

High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

“…For instance, H19 was the first lncRNA associated with cancer, which is upregulated in many types of human cancer, such as liver cancer, bladder cancer, and breast cancer, and functions as an oncogene [6,7]. Some tumor-related lncRNAs are also capable of serving as potential markers, and dysregulation of their expression is often related to the clinicopathological features and even prognosis of patients [8][9][10][11]. For example, MALAT-1 enhances the cell motility of lung adenocarcinoma and is treated as a specific marker of non-small cell lung cancer, especially in the early metastasis stage of lung adenocarcinoma [9].…”